var title_f0_45_720="Cholangioscopy-directed biopsy";
var content_f0_45_720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholangioscopy-directed biopsy of a stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fiberoptic cholangioscopy showing biopsy forceps obtaining a tissue sample from an ulcerated stricture due to cholangiocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_720=[""].join("\n");
var outline_f0_45_720=null;
var title_f0_45_721="Intestinal pseudo-obstruction in scleroderma";
var content_f0_45_721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intestinal pseudo-obstruction in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium radiograph in a patient with small bowel scleroderma and pseudo-obstruction syndrome reveals a dilated post-bulbar duodenum (megaduodenum) and jejunum, with infiltrated valvulae conniventes (white arrow) in the lower jejunal loop.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Camilleri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_721=[""].join("\n");
var outline_f0_45_721=null;
var title_f0_45_722="Port wine stain - V2 child";
var content_f0_45_722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain, represented by an erythematous patch, is present in the V2 distribution on the face of this child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_722=[""].join("\n");
var outline_f0_45_722=null;
var title_f0_45_723="EBUS tissue core";
var content_f0_45_723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endobronchial ultrasound (EBUS) tissue core",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tissue core obtained by endobronchial ultrasound-guided sampling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_723=[""].join("\n");
var outline_f0_45_723=null;
var title_f0_45_724="WHO analgesic ladder";
var content_f0_45_724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    World Health Organization (WHO) analgesic ladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_724=[""].join("\n");
var outline_f0_45_724=null;
var title_f0_45_725="Acute subacute paracocci";
var content_f0_45_725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clinical presentations of acute/subacute paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Young adults with acute/subacute paracoccidioidomycosis. A. Lymphadenopathy in the supraclavicular, cervical, and submandibular regions. B. The lymphadenopathy of paracoccidioidomycosis must be differentiated from hematologic diseases, such as lymphoma. C. Ulcerating lesions on the cheek and near the ear with a verrucous appearance resulting from hematologic dissemination. D. Papulonodular and ulcerating lesions resulting from hematologic dissemination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shikanai-Yasuda, MA, Queiroz Telles Filho, F, Mendes, RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright &copy;2006 Sociedade Brasileira de Medicina Tropical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_725=[""].join("\n");
var outline_f0_45_725=null;
var title_f0_45_726="NHLBI pediatric risk stratification associated with CVD";
var content_f0_45_726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Risk stratification and management for children with conditions predisposing to accelerated atherosclerosis and early cardiovascular disease from the 2011 NHLBI Expert Panel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 702px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Step 1:",
"    </strong>",
"    Risk stratification by disease state or condition.",
"    <br/>",
"    <strong>",
"     Step 2:",
"    </strong>",
"    Assess all cardiovascular risk factors. If there are &ge;2 comorbidities, move tier II patient to tier I for subsequent management.",
"    <br/>",
"    <strong>",
"     Step 3:",
"    </strong>",
"    Tier-specific treatment goals/cut points defined.",
"    <br/>",
"    <strong>",
"     Step 4:",
"    </strong>",
"    Initial therapy: For tier I, initial management is therapeutic lifestyle change PLUS disease-specific management. For tier II, initial management is therapeutic lifestyle change.",
"    <br/>",
"    <strong>",
"     Step 5:",
"    </strong>",
"    For tier I conditions, if goals are not met, consider pharmacological therapy.",
"    <div class=\"footnotes\">",
"     CVD: cardiovascular disease; NHLBI: National Heart, Lung, and Blood Institute; CV: cardiovascular; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; BP: blood pressure; BMI: body mass index; HgbA1c: hemoglobin A1c.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_726=[""].join("\n");
var outline_f0_45_726=null;
var title_f0_45_727="Items for nasal foreign body removal";
var content_f0_45_727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Instruments and topical anesthetic for nasal foreign body removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The headlamp frees both hands for instrumentation. When dosing the lidocaine and oxymetazoline mixture ensure no more than&nbsp;1 mg/kg (0.1 mL per kg of the 2 percent lidocaine mixture) is administered. Instruments pictured from top to bottom: right angle Day hook,&nbsp;Lucae bayonet forceps, alligator forceps.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesty of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_727=[""].join("\n");
var outline_f0_45_727=null;
var title_f0_45_728="Famotidine: Drug information";
var content_f0_45_728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Famotidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16549?source=see_link\">",
"    see \"Famotidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"    see \"Famotidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Heartburn Relief Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Heartburn Relief [OTC];",
"     </li>",
"     <li>",
"      Pepcid&reg;;",
"     </li>",
"     <li>",
"      Pepcid&reg; AC Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Pepcid&reg; AC [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Control;",
"     </li>",
"     <li>",
"      Apo-Famotidine&reg;;",
"     </li>",
"     <li>",
"      Apo-Famotidine&reg; Injectable;",
"     </li>",
"     <li>",
"      Famotidine Omega;",
"     </li>",
"     <li>",
"      Mylan-Famotidine;",
"     </li>",
"     <li>",
"      Novo-Famotidine;",
"     </li>",
"     <li>",
"      Nu-Famotidine;",
"     </li>",
"     <li>",
"      Pepcid&reg;;",
"     </li>",
"     <li>",
"      Pepcid&reg; AC;",
"     </li>",
"     <li>",
"      Pepcid&reg; I.V.;",
"     </li>",
"     <li>",
"      Ulcidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H",
"      <sub>",
"       2",
"      </sub>",
"      Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Duodenal ulcer:",
"     </b>",
"     Oral: Acute therapy: 40 mg/day at bedtime (or 20 mg twice daily) for 4-8 weeks; maintenance therapy: 20 mg/day at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric ulcer:",
"     </b>",
"     Oral: Acute therapy: 40 mg/day at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GERD:",
"     </b>",
"     Oral: 20 mg twice daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypersecretory conditions:",
"     </b>",
"     Oral: Initial: 20 mg every 6 hours, may increase in increments up to 160 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophagitis and accompanying symptoms due to GERD:",
"     </b>",
"     Oral: 20 mg or 40 mg twice daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer disease: Eradication of",
"     </b>",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: 40 mg once daily; requires combination therapy with antibiotics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress ulcer prophylaxis (unlabeled use; ASHP, 1999):",
"     </b>",
"     Oral, I.V., or nasogastric (NG) tube: 20 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Intended for patients with associated risk factors (eg, coagulopathy, mechanical ventilation for &gt;48 hours, severe sepsis); discontinue use once risk factors have resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients unable to take oral medication:",
"     </b>",
"     I.V.: 20 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heartburn, indigestion, sour stomach:",
"     </b>",
"     OTC labeling: Oral: 10-20 mg every 12 hours; dose may be taken 15-60 minutes before eating foods known to cause heartburn",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"      see \"Famotidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment duration and dose should be individualized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer:",
"     </b>",
"     1-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.5 mg/kg/day at bedtime or divided twice daily (maximum dose: 40 mg/day); doses of up to 1 mg/kg/day have been used in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.25 mg/kg every 12 hours (maximum dose: 40 mg/day); doses of up to 0.5 mg/kg have been used in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GERD:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;3 months: 0.5 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-12 months: 0.5 mg/kg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-16 years: 1 mg/kg/day divided twice daily (maximum dose: 40 mg twice daily); doses of up to 2 mg/kg/day have been used in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heartburn, indigestion, sour stomach:",
"     </b>",
"     OTC labeling: Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Manufacturer recommendation: Administer 50% of dose",
"     <b>",
"      or",
"     </b>",
"     increase the dosing interval to every 36-48 hours (to limit potential CNS adverse effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Stress ulcer prophylaxis (ASHP, 1999): Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30  mL/minute: Oral, I.V., or nasogastric (NG) tube: 20 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [preservative free]: 20 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (4 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 40 mg/5 mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg;: 40 mg/5 mL (50 mL) [contains sodium benzoate; cherry-banana-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heartburn Relief: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heartburn Relief Maximum Strength: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg [berries 'n' cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg [cool mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Infusion, Injection, oral suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with antacids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Shake vigorously before use. May be taken without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: May be taken without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: Inject over at least 2 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution for infusion: Administer over 15-30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F169985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, fat emulsion 10%, NS, sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, amsacrine, anakinra, anidulafungin, atropine, aztreonam, bivalirudin, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cisatracurium, cisplatin, cladribine, clindamycin, cyanocobalamin, cyclosporine, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, dextran 40, digoxin, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin lactobionate, esmolol, etoposide phosphate, fenoldopam, filgrastim, fluconazole, fludarabine, folic acid, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, insulin (regular), isoproterenol, labetalol, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methotrexate, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pemetrexed, phenylephrine, phytonadione, phenytoin, piperacillin, potassium chloride, potassium phosphate, procainamide, propofol, remifentanil, sargramostim, sodium bicarbonate, telavancin,  teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate potassium, tirofiban, verapamil, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, azithromycin, cefepime, piperacillin/tazobactam, sulfamethoxazole/trimethoprim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, dexamethasone sodium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance therapy and treatment of duodenal ulcer; treatment of gastroesophageal reflux disease (GERD), active benign gastric ulcer; pathological hypersecretory conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     OTC labeling: Relief of heartburn, acid indigestion, and sour stomach",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F169974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence; stress ulcer prophylaxis in critically-ill patients; symptomatic relief in gastritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7305905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Famotidine may be confused with FLUoxetine, furosemide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Agitation and vomiting have been reported in up to 14% of pediatric patients &lt;1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2%), constipation (1%), necrotizing enterocolitis (VLBW neonates; Guillet, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal discomfort, acne, agitation, agranulocytosis, allergic reaction, alopecia, anaphylaxis, angioedema, anorexia, anxiety, arrhythmia, arthralgia, AV block, bronchospasm, cholestatic jaundice, confusion, conjunctival injection, depression, dry skin, facial edema, fatigue, fever, flushing, hallucinations, hepatitis, injection site reactions, insomnia, interstitial pneumonia, leukopenia, libido decreased, liver function tests increased, muscle cramps, nausea, palpitation, pancytopenia, paresthesia, pruritus, QT-interval prolongation, rash, seizure, somnolence, Stevens-Johnson syndrome, taste disorder, tinnitus, thrombocytopenia, torsade de pointes, toxic epidermal necrolysis, urticaria, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to famotidine, other H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects.",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Confusion: Reversible confusional states, usually clearing within 3-4 days after discontinuation, have been linked to use. Increased age (&gt;50 years) and renal or hepatic impairment are thought to be associated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ECG changes: Prolonged QT interval has been reported in patients with renal dysfunction. The FDA has received reports of torsade de pointes occurring with famotidine (Poluzzi, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Multidose vials for injection contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Not for use with other acid reducers.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Famotidine bioavailability may be increased if taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, famotidine is classified as pregnancy category B. Famotidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of famotidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers, during pregnancy. Although if needed, famotidine is not the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F169911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Famotidine is excreted into breast milk with peak concentrations occurring ~6 hours after the maternal dose. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9537094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pepcid AC Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (25): $9.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pepcid AC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $16.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Famotidine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (2 mL): $1.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Famotidine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/5 mL (50 mL): $176.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Pepcid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/5 mL (50 mL): $196.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Famotidine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $1.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $173.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $335.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pepcid AC Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (25): $9.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pepcid AC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pepcid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $80.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $154.62",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Androtin (MX);",
"     </li>",
"     <li>",
"      Antiflam (UY);",
"     </li>",
"     <li>",
"      Antodine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Asid (BR);",
"     </li>",
"     <li>",
"      Aulzadin (HK);",
"     </li>",
"     <li>",
"      Ausfam (AU);",
"     </li>",
"     <li>",
"      Denufam (ID);",
"     </li>",
"     <li>",
"      Durater (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Facid (ID, IN);",
"     </li>",
"     <li>",
"      Facidex (MX);",
"     </li>",
"     <li>",
"      Fadin (TW);",
"     </li>",
"     <li>",
"      Fadine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fadul (DE);",
"     </li>",
"     <li>",
"      Famagen (KP);",
"     </li>",
"     <li>",
"      Famo (IL);",
"     </li>",
"     <li>",
"      Famoc (SG);",
"     </li>",
"     <li>",
"      Famocid (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Famodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Famodil (IT);",
"     </li>",
"     <li>",
"      Famodine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PK, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Famogal (CO);",
"     </li>",
"     <li>",
"      Famogard (RU);",
"     </li>",
"     <li>",
"      Famohexal (AU);",
"     </li>",
"     <li>",
"      Famonerton (DE);",
"     </li>",
"     <li>",
"      Famosan (CZ, EE, HR);",
"     </li>",
"     <li>",
"      Famosia (TH);",
"     </li>",
"     <li>",
"      Famotin (SG);",
"     </li>",
"     <li>",
"      Famowal (IN);",
"     </li>",
"     <li>",
"      Famox (HK, NZ, TW);",
"     </li>",
"     <li>",
"      Farotin (KP);",
"     </li>",
"     <li>",
"      Ferotine (KP);",
"     </li>",
"     <li>",
"      Fibonel (CN);",
"     </li>",
"     <li>",
"      Fudone (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Fuweidin (TW);",
"     </li>",
"     <li>",
"      Gasafe (TW);",
"     </li>",
"     <li>",
"      Gaster (CL, JP, TW);",
"     </li>",
"     <li>",
"      Gastren (PY);",
"     </li>",
"     <li>",
"      Gastridin (IT);",
"     </li>",
"     <li>",
"      Gastro (IL);",
"     </li>",
"     <li>",
"      Gastrodomina (BF, BJ, CI, ET, GH, GM, GN, HU, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Gastrum (CO);",
"     </li>",
"     <li>",
"      H2 Bloc (PH);",
"     </li>",
"     <li>",
"      Hista-Bloc (PH);",
"     </li>",
"     <li>",
"      Interfam (HK);",
"     </li>",
"     <li>",
"      Kimodin (TW);",
"     </li>",
"     <li>",
"      Logos (ZA);",
"     </li>",
"     <li>",
"      Ludex (MX);",
"     </li>",
"     <li>",
"      Modin (PH);",
"     </li>",
"     <li>",
"      Motiax (IT);",
"     </li>",
"     <li>",
"      Motidine (HK);",
"     </li>",
"     <li>",
"      Pamacid (AU);",
"     </li>",
"     <li>",
"      Pepcid (BB, BM, BS, BZ, GB, GY, JM, SE, SR, TT);",
"     </li>",
"     <li>",
"      Pepcid AC (CH, IE);",
"     </li>",
"     <li>",
"      Pepcidac (FR);",
"     </li>",
"     <li>",
"      Pepcidin (DK, FI, NL, NO, SE);",
"     </li>",
"     <li>",
"      Pepcidin Rapitab (NO);",
"     </li>",
"     <li>",
"      Pepcidina (PT);",
"     </li>",
"     <li>",
"      Pepcidine (AT, AU, BE, CH, HK, LU, MX, NZ, PE);",
"     </li>",
"     <li>",
"      Pepdif (TR);",
"     </li>",
"     <li>",
"      Pepdine (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Pepfamin (TH);",
"     </li>",
"     <li>",
"      Peptifam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Peptoci (TH);",
"     </li>",
"     <li>",
"      Peptodin (PH);",
"     </li>",
"     <li>",
"      Pepzan (MY, NZ);",
"     </li>",
"     <li>",
"      Pharmotidine (PH);",
"     </li>",
"     <li>",
"      Quamatel (HU);",
"     </li>",
"     <li>",
"      Quamtel (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Rogasti (IL);",
"     </li>",
"     <li>",
"      Sedanium-R (GR);",
"     </li>",
"     <li>",
"      Stadin (KP);",
"     </li>",
"     <li>",
"      Stomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Supertidine (TW);",
"     </li>",
"     <li>",
"      Tamin (ES);",
"     </li>",
"     <li>",
"      Topcid (IN);",
"     </li>",
"     <li>",
"      Ulcatif (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ulcelac (AR);",
"     </li>",
"     <li>",
"      Ulcenol (VE);",
"     </li>",
"     <li>",
"      Ulceran (AE, BG, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Ulfadin (CO);",
"     </li>",
"     <li>",
"      Ulfagel (EC);",
"     </li>",
"     <li>",
"      Ulfamid (HR, HU, PL);",
"     </li>",
"     <li>",
"      Ulmo (ID);",
"     </li>",
"     <li>",
"      Voker (MY);",
"     </li>",
"     <li>",
"      Weimok (TW);",
"     </li>",
"     <li>",
"      Winiful (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     receptors of the gastric parietal cells, which inhibits gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antisecretory effect: Oral: Within 1 hour; I.V.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Antisecretory effect: Oral: Within 1-3 hours (dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Antisecretory effect: I.V., Oral: 10-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Incompletely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0-3 months: ~1.4-1.8 L/kg; &gt;3-12 months: ~2.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: ~2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: ~1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal first-pass metabolism; forms one metabolite (S-oxide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 40% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0-3 months: ~8-10.5 hours; &gt;3-12 months: ~4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-3.5 hours; prolonged with renal impairment; Oliguria: &gt;20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (25% to 30% [oral], 65% to 70% [I.V.] as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad S, &ldquo;Famotidine and Cardiac Arrhythmia,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(3):315.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/2028638/pubmed\" id=\"2028638\" target=\"_blank\">",
"        2028638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and Approved by the ASHP Board of Directors on November 14, 1998,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(4):347-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/10690219/pubmed\" id=\"10690219\" target=\"_blank\">",
"        10690219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CN and Richter JE, &ldquo;Treating Gastro-oesophageal Reflux Disease During Pregnancy and Lactation: What Are the Safest Therapy Options,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1998, 19(4):325-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/9804446/pubmed\" id=\"9804446\" target=\"_blank\">",
"        9804446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fennerty MD and Higbee M, &ldquo;Drug Therapy of Gastrointestinal Disease,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 585-608.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish DN, &ldquo;Safety and Cost of Rapid I.V. Injection of Famotidine in Critically Ill Patients,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(17):1889-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/8528851/pubmed\" id=\"8528851\" target=\"_blank\">",
"        8528851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gottlieb S, Decktor DL, Eckert JM, et al, &ldquo;Efficacy and Tolerability of Famotidine in Preventing Heartburn and Related Symptoms of Upper Gastrointestinal Discomfort,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:314-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/11850669/pubmed\" id=\"11850669\" target=\"_blank\">",
"        11850669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillet R, Stoll BJ, Cotten CM, et al, \"Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/16390920/pubmed\" id=\"16390920\" target=\"_blank\">",
"        16390920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inotsume N, Mishimura M, Nakano M, et al, &ldquo;Removal of Famotidine by Haemodialysis in Elderly Anuric Patients,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1990, 38(3):313-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/2340853/pubmed\" id=\"2340853\" target=\"_blank\">",
"        2340853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James LP and Kearns GL, &ldquo;Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(2):103-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/8853932/pubmed\" id=\"8853932\" target=\"_blank\">",
"        8853932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsy RJ and Freeman CD, &ldquo;Hemodynamic Effects of Intravenous Famotidine in Critically Ill Patients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      ,1995, 15(1):48-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/7739945/pubmed\" id=\"7739945\" target=\"_blank\">",
"        7739945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poluzzi E, Raschi E, Moretti U, et al, &ldquo;Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS),&rdquo;",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2009, 18(6):512-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/19358226/pubmed\" id=\"19358226\" target=\"_blank\">",
"        19358226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon TJ, Berlin RG, Gardner AH, et al, &ldquo;Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H",
"      <sub>",
"       2",
"      </sub>",
"      -Receptor Antagonist (Famotidine),&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:304-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/11850668/pubmed\" id=\"11850668\" target=\"_blank\">",
"        11850668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treem WR, Davis PM, and Hyams JS, &ldquo;Suppression of Gastric Acid Secretion by Intravenous Administration of Famotidine in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(5):812-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/45/728/abstract-text/2019939/pubmed\" id=\"2019939\" target=\"_blank\">",
"        2019939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8436 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_728=[""].join("\n");
var outline_f0_45_728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169927\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169928\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169978\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169931\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169952\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169932\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169933\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169901\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169887\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169985\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169903\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169974\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305905\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169976\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169907\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169891\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299312\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169896\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169924\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169898\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169910\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169937\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169911\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537094\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169909\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169913\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169890\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169906\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8436|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16549?source=related_link\">",
"      Famotidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=related_link\">",
"      Famotidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_45_729="Pathophysiology of psoriasis";
var content_f0_45_729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of psoriasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/729/contributors\">",
"     Andrew Blauvelt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/729/contributors\">",
"     Benjamin D Ehst, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/729/contributors\">",
"     Kristina Callis Duffin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/729/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/45/729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12219610\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a complex autoimmune inflammatory disease that occurs in genetically susceptible individuals and presents with the development of inflammatory plaques on the skin (",
"    <a class=\"graphic graphic_picture graphicRef54581 graphicRef78531 \" href=\"UTD.htm?2/26/2473\">",
"     picture 1A-B",
"    </a>",
"    ). Although early concepts of the pathogenesis of psoriasis focused primarily on keratinocyte hyperproliferation, dysregulation of the immune system is now recognized as a critical event in this disease. The evolving knowledge of the role of the immune system in psoriasis has had a significant impact on treatment development. Many new and emerging therapeutic agents target specific immunologic aspects of psoriatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of psoriasis will be discussed here. The epidemiology, genetics, clinical features, diagnosis, and management of psoriasis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14842?source=see_link\">",
"     \"Treatment selection for moderate to severe plaque psoriasis in special populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219617\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the immune system in psoriasis was first indicated in early studies that identified complex infiltrates of leukocytes involved in both innate and adaptive immunity in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Subsequent studies have supported the concept that interactions between dendritic cells, T cells, keratinocytes, neutrophils, and the cytokines released from immune cells likely contribute to the initiation and perpetuation of the cutaneous inflammation that is characteristic of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/3\">",
"     3",
"    </a>",
"    ]. A basic sequence of the immunologic events that are theorized to occur in psoriasis is described below [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigenic stimuli contribute to the activation of plasmacytoid dendritic cells and other innate immune cells in the skin.",
"     </li>",
"     <li>",
"      Proinflammatory cytokines produced by innate immune cells, including interferon (IFN)-alpha, stimulate the activation of myeloid dendritic cells in the skin.",
"     </li>",
"     <li>",
"      Myeloid dendritic cells produce cytokines, such as interleukin (IL)-23 and IL-12 that stimulate the attraction, activation, and differentiation of T cells.",
"     </li>",
"     <li>",
"      Recruited T cells produce cytokines that stimulate keratinocytes to proliferate and produce proinflammatory antimicrobial peptides and cytokines.",
"     </li>",
"     <li>",
"      Cytokines produced by immune cells and keratinocytes perpetuate the inflammatory process via participation in positive feedback loops.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific components of this pathway are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481234\">",
"    <span class=\"h1\">",
"     THE INNATE IMMUNE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular components of the innate immune system that have been linked to the pathophysiology of psoriasis include dendritic cells, macrophages, and neutrophils. The cytokines produced by these cells that appear to play major roles in the development of psoriasis include interferon (IFN)-alpha, tumor necrosis factor (TNF)-alpha, interleukin (IL)-23, and IL-12.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481641\">",
"    <span class=\"h2\">",
"     Cellular components",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219638\">",
"    <span class=\"h3\">",
"     Dendritic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of dendritic cells (plasmacytoid dendritic cells and myeloid dendritic cells) have been implicated as contributors to psoriasis.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Plasmacytoid dendritic cells",
"      </strong>",
"      &ndash; Plasmacytoid dendritic cells are largely absent from normal human skin, but are increased in number in early lesions of psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/4\">",
"       4",
"      </a>",
"      ]. These cells are the primary producers of IFN-alpha, a key cytokine involved in the initiation of autoimmune responses and antiviral immunity. (See",
"      <a class=\"local\" href=\"#H481370\">",
"       'Interferon-alpha'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Upregulation of IFN-alpha has been detected in early psoriatic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, in a mouse xenograft model of psoriasis, the development of psoriatic lesions was dependent on IFN-alpha production by plasmacytoid dendritic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Myeloid dendritic cells",
"      </strong>",
"      &ndash; The numbers of myeloid dendritic cells are markedly elevated in psoriatic skin. In particular, an inflammatory subset of myeloid dendritic cells that is likely recruited in response to the release of IFN-alpha and other proinflammatory cytokines and chemokines has been detected in psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/7-10\">",
"       7-10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Myeloid dendritic cells are potent antigen presenting cells that produce an array of inflammatory cytokines that influence T cell activity, such as TNF-alpha. (See",
"      <a class=\"local\" href=\"#H481514\">",
"       'Tumor necrosis factor-alpha'",
"      </a>",
"      below.) Myeloid dendritic cells also produce IL-23, a cytokine that causes the differentiation of precursor CD4+ cells into Th17 cells, and IL-12, a cytokine that stimulates the development of Th1 cells and effector CD8+ T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12219645\">",
"       'Interleukin-23'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12219659\">",
"       'Interleukin-12'",
"      </a>",
"      below.) Myeloid dendritic cells also affect keratinocytes and the skin vasculature through the production of IL-20 (a modulator of keratinocyte function) and nitric oxide (a vasodilating agent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12219729\">",
"       'Keratinocytes'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12219736\">",
"       'Vascular changes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481271\">",
"    <span class=\"h3\">",
"     Macrophages and neutrophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of macrophages in psoriasis in humans is not well-understood. Macrophages accumulate in psoriatic skin near the basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/13\">",
"     13",
"    </a>",
"    ] and may contribute to psoriasis through antigen presentation to T cells as well as cytokine production. The depletion of macrophages can reverse psoriasis-like skin changes in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils are prominent in lesions of psoriasis, and are found in collections throughout the epidermis that are referred to as Munro microabscesses. The neutrophil chemoattractant IL-8 is highly elevated in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Like macrophages, neutrophils are believed to participate in psoriatic inflammation. However, it is conceivable that neutrophils do not play a central pathogenic role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481603\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481370\">",
"    <span class=\"h3\">",
"     Interferon-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I interferon pathways are upregulated in early lesions of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/5\">",
"     5",
"    </a>",
"    ]. IFN-alpha present in psoriatic skin is largely derived from plasmacytoid dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12219638\">",
"     'Dendritic cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evidence in support of a key role for IFN-alpha in psoriasis includes the observation that systemic treatment with IFN-alpha can exacerbate psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, topical treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , which induces local production of IFN-alpha in the skin, has stimulated the development of psoriasis in humans and psoriasis-like disease in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Furthermore, mice that lack a transcription factor that represses type I interferon signaling develop psoriasis-like disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481514\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha is a critical proinflammatory cytokine common to many inflammatory disease states, including psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/22\">",
"     22",
"    </a>",
"    ]. Activated dendritic cells, Th17 and Th1 cells, and keratinocytes in psoriatic skin produce TNF-alpha and respond to its effects. TNF-alpha also functions synergistically with other cytokines to promote disease pathogenesis.",
"   </p>",
"   <p>",
"    The following observations support an important role for TNF-alpha in psoriasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels of TNF-alpha are found in lesional skin of psoriatic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dramatic clinical improvement of psoriasis is seen with pharmacologic inhibitors of TNF-alpha (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Removal of circulating TNF-alpha via the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (a TNF-alpha inhibitor) results in decreased numbers of dendritic cells and T cells along with a reduction of epidermal hyperplasia in psoriatic skin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The central role of TNF-alpha in both innate and adaptive immune responses makes this cytokine an ideal target for therapeutic blockade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment of psoriasis\", section on 'Biologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219645\">",
"    <span class=\"h3\">",
"     Interleukin-23",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-23 is the cytokine responsible for proliferation and survival of Th17 cells, which is an increasingly important T cell subset in many autoimmune diseases, including psoriasis and Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. IL-23 is produced by myeloid dendritic cells and at low levels by keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Production of this cytokine by dendritic cells can occur through toll-like receptor signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of IL-23 to the pathogenesis of psoriasis has been demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In psoriatics, IL-23 is elevated in lesions of psoriasis compared with unaffected skin and localizes to dermal dendritic cells and keratinocytes; levels of IL-23 fall with effective treatment of psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/34-38\">",
"       34-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injection of IL-23 into normal mouse skin produces changes that are clinically and histologically similar to psoriasis; this process depends on downstream production of IL-22 and IL-17A [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/34,39,40\">",
"       34,39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymorphisms in the genes encoding a component of the IL-23 receptor,",
"      <em>",
"       IL23R",
"      </em>",
"      , and the p40 and p19 subunits of IL-23 have been linked to psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"       Ustekinumab",
"      </a>",
"      , a monoclonal antibody that blocks IL-23 effects on Th17 cells by inhibiting binding of IL-23 to the IL-23 receptor, has shown great efficacy in treating psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/42\">",
"       42",
"      </a>",
"      ]. Additional biologic agents that selectively block IL-23 actions hold promise for future treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H42#H42\">",
"       \"Treatment of psoriasis\", section on 'Ustekinumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219659\">",
"    <span class=\"h3\">",
"     Interleukin-12",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-12 is produced by activated myeloid dendritic cells. This cytokine promotes the differentiation of Th1 cells, which are considered important in the pathogenesis of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/42\">",
"     42",
"    </a>",
"    ]. Indirect evidence for a contributory role for IL-12 in psoriasis comes from findings of increased Th1 cells and IFN-gamma (a product of Th1 cells) in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, the degree to which IL-12 contributes to psoriasis is brought into question by the failure of a study to detect upregulation of the p35 subunit of IL-12 in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/36\">",
"     36",
"    </a>",
"    ]. It is possible that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    , an effective biologic agent for psoriasis that targets both IL-12 and IL-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], may function primarily through the drug&rsquo;s effects on the IL-23 pathway. (See",
"    <a class=\"local\" href=\"#H12219694\">",
"     'T helper type 1 cells'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12219645\">",
"     'Interleukin-23'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of psoriasis\", section on 'Ustekinumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219673\">",
"    <span class=\"h1\">",
"     THE ADAPTIVE IMMUNE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of T cells and their effector cytokines in psoriasis was established early on with the success of medications that inhibit global T cell responses, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/47\">",
"     47",
"    </a>",
"    ]. Therapies that block T cell activation or induce T cell death, such as alefacept (an inhibitor of the T cell-activating interaction between LFA3 on antigen presenting cells and CD2 on T cells that is no longer commercially available) have been effective for psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, injection of lymphocytes from psoriatics can induce psoriatic features in nonlesional human skin transplanted onto severe combined immunodeficient (SCID) mice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279163\">",
"    <span class=\"h2\">",
"     Cellular components",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219680\">",
"    <span class=\"h3\">",
"     CD4+ T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD4+ helper T cells are found throughout dermal inflammatory infiltrates in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/50\">",
"     50",
"    </a>",
"    ]. Data in support of a role for these cells include the finding that the injection of CD4+ (but not CD8+) T cells from patients with psoriasis into graft sites on SCID mice transplanted with human skin induces psoriatic changes in the engrafted skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, clinical improvement has occurred in patients with psoriasis treated with monoclonal antibodies against the CD4+ molecule on T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both Th17 and Th1 subsets of CD4+ T cells have been implicated in psoriasis. Early investigational studies presumed a dominating role for Th1 cells; however, Th17 cells are now believed to play a greater role. The effects of these cells and other components of the adaptive immune system in psoriasis are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219687\">",
"    <span class=\"h4\">",
"     T helper type 17 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of Th17 cells has led to important insights on the pathophysiology of psoriasis and new target-specific approaches to treatment. Th17 cells develop in psoriatic skin under the polarizing effects of IL-1, IL-6, transforming growth factor (TGF)-beta, and IL-23 produced by inflammatory dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12219638\">",
"     'Dendritic cells'",
"    </a>",
"    above.) The activation of Th17 cells by IL-23 stimulates these cells to produce IL-17A and IL-22, cytokines that promote keratinocyte activation and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/39,54,55\">",
"     39,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12219701\">",
"     'Interleukin-17A'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12219708\">",
"     'Interleukin-22'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following study results highlight the role of these cells in psoriasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Th17 cells produce an array of proinflammatory cytokines, including IL-17A, IL-17F, IL-21, IL-22, IL-6, and TNF-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/29\">",
"       29",
"      </a>",
"      ], all of which have been linked to psoriasis.",
"     </li>",
"     <li>",
"      Th17 cells are found in lesional skin and at elevated levels in the circulation in patients with psoriasis, and IL-17A is abundantly expressed by these cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/43,56,57\">",
"       43,56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transgenic mice overexpressing the p19 subunit of IL-23, a key factor for Th17 cell functioning, have severe widespread inflammatory disease that includes inflammation of the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Effective therapies for psoriasis, such as phototherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , have all been shown to modulate the Th17 pathway in psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/9,57,59-61\">",
"       9,57,59-61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Selective targeting of Th17 cells via inhibition of IL-23, the IL-23 receptor, or IL-17A is a promising therapeutic approach for psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    , a highly effective drug that is currently in use for psoriasis, is a monoclonal antibody that binds to IL-23. Agents that interrupt",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    signaling pathways (key intracellular events in Th17 cytokine production) are also under investigation for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219694\">",
"    <span class=\"h4\">",
"     T helper type 1 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th1 cells produce an array of proinflammatory cytokines, including IFN-gamma, IL-2, and TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/42\">",
"     42",
"    </a>",
"    ]. IFN-gamma, the prototypic cytokine produced by these cells, can promote psoriasis-like changes in nonlesional psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/65\">",
"     65",
"    </a>",
"    ]. Of note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , an effective anti-TNF therapy for psoriasis, is also capable of inhibiting IFN-gamma production by Th1 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-12, a cytokine produced by activated myeloid dendritic cells, promotes the differentiation of Th1 cells. The degree to which IL-12-mediated effects contribute to psoriasis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12219638\">",
"     'Dendritic cells'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12219659\">",
"     'Interleukin-12'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280083\">",
"    <span class=\"h3\">",
"     CD8 T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic CD8+ T cells are found primarily in the epidermis of psoriatic skin and are generally considered to play a less prominent role in psoriasis than CD4+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/67\">",
"     67",
"    </a>",
"    ]. Although they produce cytolytic enzymes, their role in psoriasis is speculated to involve the elaboration of inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Interestingly, clonal restriction of psoriatic T cells seems limited to the CD8+ compartment. This finding might suggest a link between viral or self antigens in the epidermis and triggering of psoriasis, since these types of MHC class I-restricted antigens are typically presented to CD8+ T cells, and not CD4+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280090\">",
"    <span class=\"h3\">",
"     Regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD18-knockout mice that are deficient in regulatory T cells develop skin with features of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/73\">",
"     73",
"    </a>",
"    ]. Additionally, defects in the suppressive function of regulatory T cells have been found in psoriasis lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/74\">",
"     74",
"    </a>",
"    ]. In the absence of properly functioning regulatory cells, downregulation of immune responses is inadequate. This may contribute to unchecked inflammation in psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280183\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219701\">",
"    <span class=\"h3\">",
"     Interleukin-17A",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-17A, a cytokine produced by Th17 cells, is elevated in lesions of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/34,75\">",
"     34,75",
"    </a>",
"    ]. IL-17A has many functions that are relevant to psoriasis, including the activation, recruitment, and inhibition of apoptosis in neutrophils; the enhancement of angiogenesis; the promotion of the release of other inflammatory cytokines (TNF-alpha, IL-1, and IL-6); and the direct activation of keratinocytes leading to increased production of chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/39,55,76-82\">",
"     39,55,76-82",
"    </a>",
"    ]. Therapeutic agents for psoriasis that block IL-17 production or the downstream effects of IL-17 are in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/62\">",
"     62",
"    </a>",
"    ]. Phase II trials have demonstrated efficacy of an anti-IL-17 monoclonal antibody (ixekizumab) and an anti-IL-17 receptor antibody (brodalumab) in moderate to severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219708\">",
"    <span class=\"h3\">",
"     Interleukin-22",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-22 levels are increased in the blood of patients with psoriasis and in psoriatic plaques. Treatment of psoriasis decreases these levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/57,75,85\">",
"     57,75,85",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    IL-22 is produced by Th17 cells and Th22 cells. This cytokine stimulates the growth and activation of keratinocytes and has little effect on immune cells. In keratinocytes, IL-22-mediated signaling via STAT3 stimulates cell hyperproliferation, secretion of antimicrobial peptides, and production of matrix metalloproteinases that support increased cell mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/40,85-88\">",
"     40,85-88",
"    </a>",
"    ]. Molecular therapies that target IL-22 are in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219729\">",
"    <span class=\"h1\">",
"     KERATINOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for epidermal keratinocytes as triggers for the initiation of psoriasis is a subject of much debate. Keratinocyte-derived antimicrobial peptides (AMPs), including beta-defensins, cathelicidins, and psoriasin (S100A7), may be induced by trauma, and are upregulated in psoriatic epidermis early in the course of lesion development [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/90\">",
"     90",
"    </a>",
"    ]. AMPs have both chemoattractant and immunomodulatory effects on dendritic cells and T cells and may contribute to cutaneous inflammation. One theory on the initiation of psoriasis involves the upregulation of the AMP cathelicidin LL-37 in skin. LL-37 may bind self DNA and stimulate the production of IFN-alpha by plasmacytoid dendritic cells through Toll-like receptor (TLR)-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Keratinocyte hyperplasia characteristic of psoriasis may develop as a result of the effects of cytokines produced by immune cells. IL-22 is produced by Th17 cells and promotes many of the epidermal changes that occur in psoriatic lesions. (See",
"    <a class=\"local\" href=\"#H12219708\">",
"     'Interleukin-22'",
"    </a>",
"    above.) Additionally, IL-20 production by keratinocytes plays an important synergistic role downstream of IL-22.",
"   </p>",
"   <p>",
"    Both IL-22 and IL-20 are highly expressed in psoriatic skin and promote alterations in epidermal thickness, maturation defects, and upregulation of AMPs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. A role for IL-20 in psoriasis is supported by the observation that blocking IL-20 in a SCID xenotransplant model of psoriasis induces resolution of psoriasis and blocks initiation of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/94\">",
"     94",
"    </a>",
"    ]. Therapeutics directed against both IL-22 and IL-20 have been tested in early clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytokines and chemokines produced by activated keratinocytes contribute to the sustainment of the inflammatory response in psoriasis via their effects on innate and adaptive immune cells. Topical vitamin D analogs as well as topical and oral retinoids primarily affect this pathway in psoriasis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    was originally thought to modulate the epidermal component of psoriasis as well, although current thinking suggests that its direct effects on the immune system are more important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of psoriasis\", section on 'Topical vitamin D analogs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of psoriasis\", section on 'Tazarotene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of psoriasis\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219736\">",
"    <span class=\"h1\">",
"     VASCULAR CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial cells within psoriatic plaques express elevated levels of vascular endothelial growth factor (VEGF), prostaglandins, and nitric oxide, all contributing to the characteristic leaky and tortuous vessels that are abundant in psoriatic skin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Transgenic mice overexpressing VEGF in the epidermis have been found to develop psoriasiform skin changes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activated vasculature promotes attraction and transmigration of the leukocytes discussed above. Antiangiogenic agents have actually demonstrated some success in psoriasis patients, but more investigation is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219743\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications, trauma, alcohol, cigarette smoking, stress, and infections have all been linked to the onset of autoimmune inflammatory conditions and are also known to trigger psoriasis. The current understanding of this process is rudimentary.",
"   </p>",
"   <p>",
"    A proposed pathogenic model highlights the possibility of innate recognition of conserved sequences in microbes through TLR signaling as one possible explanation for infectious triggers. The",
"    <span class=\"nowrap\">",
"     TLR-7/8",
"    </span>",
"    antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    can induce a psoriasis-like skin disease in mice through production of IFN-alpha by plasmacytoid dendritic cells. This process is dependent on the Th17 pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/729/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12219750\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoriasis is a complex immune-mediated disorder that presents as inflammatory plaques in the skin (",
"      <a class=\"graphic graphic_picture graphicRef54581 graphicRef78531 \" href=\"UTD.htm?2/26/2473\">",
"       picture 1A-B",
"      </a>",
"      ). Dysregulation or alteration of components of the innate and adaptive immune systems, keratinocyte function, and vascular structure contribute to the manifestations of this disease. (See",
"      <a class=\"local\" href=\"#H12219617\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasmacytoid and myeloid dendritic cells are key contributors to development of inflammation in psoriasis. IFN-alpha produced by plasmacytoid dendritic cells stimulates the activation of myeloid dendritic cells, which contribute to the adaptive immune response through the activation of T cells. (See",
"      <a class=\"local\" href=\"#H481234\">",
"       'The innate immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IL-23 and IL-12 produced by activated myeloid dendritic cells promote the development of Th17 and Th1 cells, respectively. Th17 cells appear to play a major role in the pathogenesis of psoriasis. (See",
"      <a class=\"local\" href=\"#H12219673\">",
"       'The adaptive immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Keratinocytes may contribute to the initiation of psoriasis via the production of antimicrobial peptides. Epidermal hyperplasia is driven by cytokines that stimulate keratinocyte activation and proliferation. (See",
"      <a class=\"local\" href=\"#H12219729\">",
"       'Keratinocytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knowledge of the pathophysiology of psoriasis is evolving. Advances in the understanding of the mechanisms of disease will likely contribute to the development of new therapeutic agents and improved patient outcomes. (See",
"      <a class=\"local\" href=\"#H12219610\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"       \"Treatment of psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/1\">",
"      Bos JD, Hulsebosch HJ, Krieg SR, et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/2\">",
"      Braun-Falco O, Burg G. [Inflammatory infiltrate in psoriasis vulgaris. A cytochemical study]. Arch Klin Exp Dermatol 1970; 236:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/3\">",
"      Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/4\">",
"      Wollenberg A, Wagner M, G&uuml;nther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/5\">",
"      van der Fits L, van der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004; 122:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/6\">",
"      Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/7\">",
"      Farkas A, Kem&eacute;ny L. Interferon-&alpha; in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br J Dermatol 2011; 165:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/8\">",
"      Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005; 102:19057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/9\">",
"      Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/10\">",
"      Zaba LC, Krueger JG, Lowes MA. Resident and \"inflammatory\" dendritic cells in human skin. J Invest Dermatol 2009; 129:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/11\">",
"      McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/12\">",
"      Wang F, Lee E, Lowes MA, et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 2006; 126:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/13\">",
"      Boehncke WH, Wortmann S, Kaufmann R, et al. A subset of macrophages located along the basement membrane (\"lining cells\") is a characteristic histopathological feature of psoriasis. Am J Dermatopathol 1995; 17:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/14\">",
"      Wang H, Peters T, Kess D, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006; 116:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/15\">",
"      Glowacka E, Lewkowicz P, Rotsztejn H, Zalewska A. IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 2010; 55:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/16\">",
"      van de Kerkhof PC, Lammers AM. Intraepidermal accumulation of polymorphonuclear leukocytes in chronic stable plaque psoriasis. Dermatologica 1987; 174:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/17\">",
"      Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol 1991; 125:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/18\">",
"      Ketikoglou I, Karatapanis S, Elefsiniotis I, et al. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/19\">",
"      Patel U, Mark NM, Machler BC, Levine VJ. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011; 164:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/20\">",
"      van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182:5836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/21\">",
"      Hida S, Ogasawara K, Sato K, et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000; 13:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/22\">",
"      Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/23\">",
"      Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/24\">",
"      Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/25\">",
"      Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/26\">",
"      Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/27\">",
"      Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/28\">",
"      Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/29\">",
"      Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/30\">",
"      Gerosa F, Baldani-Guerra B, Lyakh LA, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008; 205:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/31\">",
"      Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/32\">",
"      Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006; 177:7980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/33\">",
"      Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276:37692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/34\">",
"      Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/35\">",
"      Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005; 102:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/36\">",
"      Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/37\">",
"      Piskin G, Tursen U, Sylva-Steenland RM, et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23. Exp Dermatol 2004; 13:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/38\">",
"      Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177:4917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/39\">",
"      Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011; 186:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/40\">",
"      Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/41\">",
"      Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4:e1000041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/42\">",
"      Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/43\">",
"      Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/44\">",
"      Szabo SK, Hammerberg C, Yoshida Y, et al. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998; 111:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/45\">",
"      Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/46\">",
"      Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol 2010; 185:5688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/47\">",
"      Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/48\">",
"      Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/49\">",
"      Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/50\">",
"      Nikaein A, Phillips C, Gilbert SC, et al. Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol 1991; 96:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/51\">",
"      Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/52\">",
"      Gottlieb AB, Lebwohl M, Shirin S, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/53\">",
"      Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/54\">",
"      Chiricozzi A, Guttman-Yassky E, Su&aacute;rez-Fari&ntilde;as M, et al. Integrative responses to IL-17 and TNF-&alpha; in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/55\">",
"      Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/56\">",
"      Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/57\">",
"      Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/58\">",
"      Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 2001; 166:7563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/59\">",
"      Haider AS, Lowes MA, Su&aacute;rez-Fari&ntilde;as M, et al. Identification of cellular pathways of \"type 1,\" Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/60\">",
"      R&aacute;cz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011; 131:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/61\">",
"      Zaba LC, Su&aacute;rez-Fari&ntilde;as M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/62\">",
"      Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/63\">",
"      Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011; 12:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/64\">",
"      Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol 2008; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/65\">",
"      Wei L, Debets R, Hegmans JJ, et al. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 1999; 187:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/66\">",
"      Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 2008; 128:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/67\">",
"      Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/68\">",
"      Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007; 13:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/69\">",
"      Ortega C, Fern&aacute;ndez-A S, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/70\">",
"      Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/71\">",
"      Lin WJ, Norris DA, Achziger M, et al. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 2001; 117:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/72\">",
"      Prinz JC, Vollmer S, Boehncke WH, et al. Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 1999; 29:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/73\">",
"      Wang H, Peters T, Sindrilaru A, et al. TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest 2008; 118:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/74\">",
"      Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/75\">",
"      Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/76\">",
"      Albanesi C, Scarponi C, Cavani A, et al. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000; 115:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/77\">",
"      Dragon S, Saffar AS, Shan L, Gounni AS. IL-17 attenuates the anti-apoptotic effects of GM-CSF in human neutrophils. Mol Immunol 2008; 45:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/78\">",
"      Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164:6621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/79\">",
"      Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/80\">",
"      Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/81\">",
"      Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004; 279:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/82\">",
"      Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002; 169:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/83\">",
"      Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/84\">",
"      Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/85\">",
"      Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/86\">",
"      Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174:3695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/87\">",
"      Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/88\">",
"      Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/89\">",
"      Nograles KE, Krueger JG. Anti-cytokine therapies for psoriasis. Exp Cell Res 2011; 317:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/90\">",
"      Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/91\">",
"      Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/92\">",
"      Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/93\">",
"      Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39:3570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/94\">",
"      Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009; 160:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/95\">",
"      Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007; 10:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/96\">",
"      Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/97\">",
"      Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/729/abstract/98\">",
"      Ehrlich A, Booher S, Becerra Y, et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004; 50:533.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15277 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_729=[""].join("\n");
var outline_f0_45_729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12219750\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219610\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219617\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481234\">",
"      THE INNATE IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481641\">",
"      Cellular components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219638\">",
"      - Dendritic cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H481271\">",
"      - Macrophages and neutrophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481603\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H481370\">",
"      - Interferon-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H481514\">",
"      - Tumor necrosis factor-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219645\">",
"      - Interleukin-23",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219659\">",
"      - Interleukin-12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219673\">",
"      THE ADAPTIVE IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1279163\">",
"      Cellular components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219680\">",
"      - CD4+ T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12219687\">",
"      T helper type 17 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12219694\">",
"      T helper type 1 cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1280083\">",
"      - CD8 T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1280090\">",
"      - Regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1280183\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219701\">",
"      - Interleukin-17A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12219708\">",
"      - Interleukin-22",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219729\">",
"      KERATINOCYTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219736\">",
"      VASCULAR CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219743\">",
"      ENVIRONMENTAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12219750\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15277|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/28/33219\" title=\"picture 1A\">",
"      Psoriasis plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/48/31492\" title=\"picture 1B\">",
"      Inverse psoriasis chest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14842?source=related_link\">",
"      Treatment selection for moderate to severe plaque psoriasis in special populations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_45_730="Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia";
var content_f0_45_730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/730/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/730/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/730/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/45/730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/45/730/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/45/730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the causes of Cushing's syndrome are three rare types of nodular adrenocortical diseases that are usually bilateral:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticotropin (ACTH)-dependent bilateral macronodular hyperplasia secondary to long-term adrenal stimulation in patients with Cushing's disease or ectopic ACTH syndrome.",
"     </li>",
"     <li>",
"      ACTH-independent micronodular adrenal hyperplasia and its most frequent variant primary pigmented nodular adrenocortical disease (PPNAD), which may be sporadic or familial (as part of the Carney complex).",
"     </li>",
"     <li>",
"      ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACTH-independent bilateral macronodular adrenal hyperplasia will be reviewed here. Other causes of Cushing's syndrome, and primary pigmented nodular adrenocortical disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTH-independent macronodular adrenal hyperplasia (AIMAH) has been described by various terms, including massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and \"giant\" or \"huge\" macronodular adrenal disease. AIMAH results in hypercortisolism through a number of mechanisms that are described below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    AIMAH is associated with adrenal glands weighing from 24 to 500 g that contain multiple nonpigmented nodules greater than 5 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The nodules appear to be typical benign adrenal nodules, but the internodular cortex may be either hyperplastic or atrophic.",
"   </p>",
"   <p>",
"    Most patients with AIMAH and Cushing&rsquo;s syndrome present in the fifth and sixth decades [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], a later age of onset compared with unilateral cortisol-producing adenomas, PPNAD or pituitary corticotroph adenomas (Cushing's disease). The majority of patients with AIMAH have only subclinical cortisol production and present with bilateral adrenal incidentalomas [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Biochemical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings in AIMAH with overt Cushing's syndrome are the same as those seen in ACTH-independent Cushing's syndrome with unilateral tumors and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased serum and urinary cortisol and undetectable plasma ACTH in the basal state and after administration of corticotropin-releasing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cortisol production is not suppressed by low or high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      An exception to this general pattern occurs in patients with gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome in whom cortisol hypersecretion occurs in response to meals and serum cortisol may be low in the fasting state [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Steroid hormone synthesis is relatively inefficient in AIMAH, as a consequence of decreased steroidogenic enzymatic activity resulting frequently in elevated 17-hydroxyprogesterone levels after stimulation with ACTH [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. This probably explains why urinary 17-hydroxycorticosteroids (17-OHCS), which also measure precursor steroids, are more often elevated than urinary free cortisol levels in AIMAH [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum aldosterone, 18-hydroxycorticosterone, corticosterone, and estrone may cause hypertension or feminization in the rare patients in whom they are increased [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case of bilateral massive AIMAH in a male patient was found to produce large amounts of adrenal androgens without any cortisol excess or clinical symptoms and was detected only as bilateral incidentaloma [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AIMAH can be distinguished from ACTH-dependent macronodular hyperplasia by measuring plasma ACTH. Plasma ACTH is suppressed by excess cortisol in AIMAH (&lt;5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [&lt;1.1",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    and is inappropriately normal or high in ACTH-dependent macronodular hyperplasia (&ge;15",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [3.3",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    Rare patients with ACTH-dependent hyperplasia have low, but consistently detectable plasma ACTH concentrations (&le;10",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [2.8",
"    <span class=\"nowrap\">",
"     pmol/L]),",
"    </span>",
"    presumably due to its suppression by some of their adrenal nodules, which have acquired the capacity to secrete cortisol \"autonomously\" or constitutively by unidentified mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with primary bilateral macronodular adrenal hyperplasia have subclinical Cushing's syndrome and, therefore, their ACTH levels may not be suppressed, particularly when urine free cortisol is still in the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8\">",
"     8",
"    </a>",
"    ]. In these patients, low or high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    will produce partial suppression of cortisol, but not to less than 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the morning following night-time dexamethasone administration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both aberrant hormone receptors and genetic mutations have been identified in the pathogenesis of ACTH-independent macronodular adrenal hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aberrant hormone receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most prevalent abnormality in patients with AIMAH results from the aberrant adrenal expression of ectopic or increased activity of eutopic peptide hormone receptors&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65003 \" href=\"UTD.htm?5/58/6061\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cortisol secretion becomes driven by a hormone that escapes cortisol-mediated feedback.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596836211\">",
"    <span class=\"h3\">",
"     Receptor types",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     GIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ectopic expression of glucose-dependent insulinotropic peptide (also known as gastric inhibitory polypeptide or GIP) receptor in zona fasciculata cells causes \"food-dependent\" cortisol production.",
"   </p>",
"   <p>",
"    Plasma cortisol levels may be relatively low during fasting and increase transiently following meals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/6,7,17\">",
"     6,7,17",
"    </a>",
"    ]. GIP-dependent Cushing's syndrome has been identified in approximately 20 patients with AIMAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/6,7,17-21\">",
"     6,7,17-21",
"    </a>",
"    ]. GIP receptors are not expressed in the normal adult or fetal zona fasciculata [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/17-20,22\">",
"     17-20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aberrant GIP receptor expression has also been identified in unilateral adrenal adenomas causing Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/6,7,17-20\">",
"     6,7,17-20",
"    </a>",
"    ] or primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/22\">",
"     22",
"    </a>",
"    ], although this is rare: only 1 of 16 adenomas in one series expressed the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/18\">",
"     18",
"    </a>",
"    ]. The adrenal nodules in rare patients with AIMAH can progress asynchronously, first in one adrenal, later in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/20\">",
"     20",
"    </a>",
"    ]; in one report, the adrenal adjacent to the macronodules was not atrophic, but showed diffuse adrenal hyperplasia with ectopic GIP receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/20\">",
"     20",
"    </a>",
"    ], suggesting that larger nodules were the result of secondary clonal proliferation events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reported cases include a patient with GIP-dependent androgen and cortisol secretion in an adrenal adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/24\">",
"     24",
"    </a>",
"    ], and patients with combined aberrant expression of GIP receptor and",
"    <span class=\"nowrap\">",
"     LH/hCG",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] or with leptin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for overexpression of the GIP receptor (GIPR) are not known. Thus far, GIPR gene mutations have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/28\">",
"     28",
"    </a>",
"    ]. One study suggested that chronic stimulation by ACTH in Cushing's disease could lead to increased GIPR expression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/29\">",
"     29",
"    </a>",
"    ], but others did not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/19,30,31\">",
"     19,30,31",
"    </a>",
"    ]. Several genes have been identified that are differentially expressed in GIP-dependent AIMAH or unilateral adenomas, compared with normal adrenals, or those in Cushing's disease, and form the basis to investigate which one is specifically implicated in the ectopic expression of GIPR in the adrenal fasciculata [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/23,32\">",
"     23,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercortisolism due to ectopic GIP receptor expression has also been demonstrated in an animal model. Bovine adrenal cells transfected with the GIP receptor and injected under the renal capsule of nude mice generate adrenal-like hyperplastic nodules that produce glucocorticoid excess [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Vasopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin-responsive Cushing's syndrome has been reported in several patients with AIMAH or a unilateral adenoma. In these patients, cortisol secretion increased with upright posture or other physiological stimuli of endogenous vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,15,16,25,34-40\">",
"     8,15,16,25,34-40",
"    </a>",
"    ]. In most, cortisol secretion was regulated by the V1-vasopressin receptor, expressed at either normal or high levels.",
"   </p>",
"   <p>",
"    The V1-vasopressin receptor is normally expressed in the adrenal cortex but is not a major regulator of steroidogenesis. In the patients with AIMAH, the exaggerated steroidogenic responses to vasopressin are secondary to the increased activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expression of a \"eutopic\" receptor-effector system. One patient had orthostatic hypotension that persisted after bilateral adrenalectomy, suggesting a possible alteration in adrenal and vascular responses of the vasopressin signal transduction pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ectopic expression of V2- and V3-vasopressin receptors has been reported in some AIMAH cases. The significance of this finding is unclear, because a cortisol response was not observed when dDAVP, a preferential V2-vasopressin receptor agonist, was administered to some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, in vitro studies suggest that in some cases of AIMAH, vasopressin hyper-responsiveness is mediated by V2-vasopressin receptor, while V1-vasopressin receptor can be repressed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Beta adrenergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIMAH and Cushing's syndrome have been reported in patients with aberrant adrenal expression of beta-adrenergic receptors. In one patient, plasma cortisol and aldosterone levels increased in response to an increase in endogenous catecholamines (upright posture, insulin-induced hypoglycemia and exercise) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     Isoproterenol",
"    </a>",
"    infusion stimulated cortisol and aldosterone secretion in this patient, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    blocked this effect and reduced basal cortisol secretion with long-term control of hypercortisolism. These effects were not seen in normal subjects.",
"   </p>",
"   <p>",
"    Similar findings have been reported in other patients with AIMAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/36,38,43\">",
"     36,38,43",
"    </a>",
"    ]. High affinity binding sites compatible with beta-1- or beta-2-adrenergic receptors were efficiently coupled to steroidogenesis in the adrenal tissues in these patients, but not in controls, indicating the ectopic nature of this receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/38,42,43\">",
"     38,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combined presence of adrenal beta-adrenergic receptor and V1-vasopressin receptor has been observed in other patients with AIMAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/36,38,43\">",
"     36,38,43",
"    </a>",
"    ]; fluctuations of endogenous physiological levels of vasopressin (water and hypertonic sodium loading) resulted in parallel changes of plasma cortisol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/36\">",
"     36",
"    </a>",
"    ]. In one patient with AIMAH, the combined overexpression of beta-2-adrenoreceptor, of serotonin 5HT4 receptor, and V1- vasopressin receptor was demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     LH/hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercortisolism due to aberrant",
"    <span class=\"nowrap\">",
"     LH/hCG",
"    </span>",
"    receptors was first identified in a woman with transient Cushing's syndrome during sequential pregnancies. Persistent Cushing's syndrome and AIMAH developed only after the postmenopausal sustained increase of LH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/45\">",
"     45",
"    </a>",
"    ]. Administration of the long-acting GnRH agonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate, resulted in suppression of endogenous LH and normalization of cortisol production [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 59-year old virilized woman with androgen-secreting AIMAH regulated by hCG was shown to express the",
"    <span class=\"nowrap\">",
"     LH/hCG",
"    </span>",
"    receptor in one resected adrenal; suppression of endogenous LH with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate normalized androgen secretion from the contralateral adrenal, avoiding bilateral adrenalectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cases of aberrant receptors for",
"    <span class=\"nowrap\">",
"     LH/hCG",
"    </span>",
"    or serotonin either alone or in combination have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,25,47\">",
"     8,25,47",
"    </a>",
"    ]. In the patient described above [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/45\">",
"     45",
"    </a>",
"    ], serotonin 5-HT4 receptor agonists, cisapride and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , also stimulated plasma cortisol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial description of combined aberrant LH and serotonin 5-HT4 receptors in AIMAH, several other patients were found to have increased secretion of cortisol following stimulation with cisapride,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"     tegaserod",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,25,40,47-50\">",
"     8,25,40,47-50",
"    </a>",
"    ]. In most cases, a large overexpression of 5-HT4 receptor was found in the adrenals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The ectopic expression and function of 5-HT7 receptor was identified in a patient with serotonin-responsive AIMAH and Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/50\">",
"     50",
"    </a>",
"    ] and in one patient with adrenal carcinoma who also secreted renin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Angiotensin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with AIMAH and a large increase in plasma aldosterone and cortisol levels during upright posture, short-term oral administration of the angiotensin-1 receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    completely inhibited the elevation in cortisol and aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/55\">",
"     55",
"    </a>",
"    ]. In vitro stimulation of cortisol secretion by angiotensin-II was also found in patients with AIMAH and Cushing's syndrome who had increases in cortisol levels with upright posture [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428975\">",
"    <span class=\"h3\">",
"     Systematic screening for aberrant receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In series of patients with AIMAH who underwent screening for aberrant receptors, more than 85 percent were found to have at least one and usually several aberrant responses; the most frequent were those to vasopressin, serotonin-4 agonists (patients with Cushing&rsquo;s syndrome), and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (in subclinical cortisol secretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/9,10,36\">",
"     9,10,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that looked to identify novel abnormally expressed G protein-coupled receptors (GPCRs) in patients with AIMAH, several new aberrant receptor genes were identified, one of which (the a2A adrenergic receptor [ADRA2A], highly expressed in 13 of 18 AIMAHs) may be a potential target for pharmacologic treatment of Cushing&rsquo;s syndrome due to AIMAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/56\">",
"     56",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     Clonidine",
"    </a>",
"    (an ADRA2A agonist) administration resulted in an increase in cortisol production; the increase could be blocked by an ADRA2A antagonist, yohimbine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596836184\">",
"    <span class=\"h2\">",
"     Paracrine mechanisms in AIMAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracrine regulatory mechanisms were suggested in some AIMAH cases after the demonstration of increased adrenocortical expression of",
"    <span class=\"nowrap\">",
"     pro-opiomelanocortin/ACTH,",
"    </span>",
"    serotonin or vasopressin in some affected AIMAH tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/50,57\">",
"     50,57",
"    </a>",
"    ]. Thus, in addition to the aberrant expression of diversified hormone receptors, the local adrenal (adrenal cortex, adrenal medulla, and adrenal",
"    <span class=\"nowrap\">",
"     tumor/hyperplasia)",
"    </span>",
"    production of ligands for these receptors could allow an important contribution of paracrine or autocrine regulation in addition to the hormonal regulation of circulating hormones for these receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several molecular causes have been identified in the pathogenesis of ACTH-independent macronodular adrenal hyperplasia indicating that it is a heterogeneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gs alpha-subunit mutations &mdash; Cushing's syndrome associated with McCune-Albright syndrome (MAS) is a rare variant of AIMAH. MAS is a sporadic disease characterized by polyostotic fibrous dysplasia with caf&eacute; au lait spots, sexual precocity, and other endocrine and nonendocrine disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H3989453#H3989453\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'McCune-Albright syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the blastocyst phase of embryogenesis, an activating somatic Arg201Cys or Arg201His mutation of the gene coding for the alpha-subunit stimulatory guanine nucleotide-binding protein, Gs, occurs in some adrenal cells in a mosaic pattern, which leads to the formation of adrenal nodules. Constitutive activation of the cAMP pathway in the nodules leads to excess cortisol secretion and ACTH suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/59\">",
"     59",
"    </a>",
"    ]; the internodular adrenal cortex, where the Gsa mutation is not present, becomes atrophic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ten patients with Cushing's syndrome and MAS have been reported, five males and five females, eight of whom were less than six months old. Activating mutations of Gsa have been occasionally found in the AIMAH nodules of pediatric or adult patients without any other features of McCune-Albright syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN1 &mdash; Bilateral adrenal nodules have also been described as part of multiple endocrine neoplasia syndrome type 1 (MEN1), which is caused by the tumor suppressor gene menin. In a series of 33 MEN1 patients, bilateral adrenal enlargement was found in 21 percent; more than half of the remaining patients also had unilateral adenomas or carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/62\">",
"       62",
"      </a>",
"      ]. Similarly, in 33 patients from a single kindred with MEN1, the overall prevalence of adrenal disease was 36 percent; bilateral macronodular cortical hyperplasia was present in 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/52\">",
"       52",
"      </a>",
"      ]. In the vast majority of MEN1 patients with adrenal lesions, there was no evidence of abnormal hormone secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"      </a>",
"      .) However, some cases of AIMAH with Cushing&rsquo;s syndrome were found to have MEN1 or MEN1-like syndrome (hyperparathyroidism, insulinomas",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pituitary tumors) with or without MEN1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/10,63-65\">",
"       10,63-65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MC2R gene &mdash; There are rare reports of activating mutations of the ACTH receptor (MC2R) gene in adrenal tumors. In one case of AIMAH, a MC2R mutation (F278C) was associated with elevated basal cAMP production when compared with wild-type receptor-expressing cell lines. This mutation in the C-terminal tail of the MC2R impaired desensitization and internalization of the receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Two mutations in the same allele of the MC2R associated with clinical hypersensitivity to ACTH have been described in a single case report. The presence of both C21R and S247G mutations in the same molecule leads to a receptor with a highly significant elevation in constitutive activity; the co-expression of the normal MC2R allele results in the retention of a normal dose response to ACTH despite the presence of constitutive activity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/66\">",
"       66",
"      </a>",
"      ]. In one case of AIMAH, an increase in mRNA for MC2R was suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/67\">",
"       67",
"      </a>",
"      ], but in other series of patients with AIMAH, MC2R levels were decreased [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/23,68\">",
"       23,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other genes &mdash; AIMAH or adrenal nodules have been reported in patients with familial polyposis coli and a mutation in the adenomatous polyposis coli (APC) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/10,69\">",
"       10,69",
"      </a>",
"      ] and with hereditary leiomyomatosis and renal cell cancer disorders due to mutations in the fumarate hydratase gene (FH) on chromosome 1q42.3-43 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/70\">",
"       70",
"      </a>",
"      ]. Missense germline mutations in phosphodiesterase 11A isoform 4 gene (PDE11A) located on chromosome 2q31-35 have been identified initially in kindreds with non-pigmented micronodular hyperplasia but have now been found at higher frequency in patients with various adrenocortical tumors including bilateral macronodular adrenal hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/71\">",
"       71",
"      </a>",
"      ]. Differential expression of several microRNAs were identified in AIMAH tissues and some appeared to be correlated with severity of disease and hypercortisolism [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Familial forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most initial cases of AIMAH appeared to be sporadic; however, family screening was not performed systematically [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There are now several reports of familial cases of AIMAH whose presentation suggests autosomal dominant transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/38-40,73-77\">",
"     38-40,73-77",
"    </a>",
"    ]. As noted above, AIMAH is probably genetically heterogeneous with occasional cases that occur in association with other syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/10,52,62,69,70,78\">",
"     10,52,62,69,70,78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Genetic causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In familial cases of isolated AIMAH, a number of aberrant hormone receptors have been identified in individual families, including V1-V2- and V3-vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/39\">",
"     39",
"    </a>",
"    ], beta-adrenergic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/76\">",
"     76",
"    </a>",
"    ], combined V1-vasopressin and beta-adrenergic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/38\">",
"     38",
"    </a>",
"    ], and combined 5HT4 and V1-V-2 vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/40\">",
"     40",
"    </a>",
"    ]. The germline transmission of the same receptors' phenotype in all affected family members support a primary role of aberrant receptors in the pathophysiology of this type of AIMAH. The prevalence of familial forms of AIMAH are not known yet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation and biochemical findings of Cushing's syndrome in AIMAH are similar to that seen in other types of ACTH-independent Cushing's syndrome, as described above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical features'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    AIMAH can be distinguished from ACTH-dependent macronodular hyperplasias by measuring plasma ACTH. Plasma ACTH is suppressed by excess cortisol in AIMAH (&lt;5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [&lt;1.1",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    and is inappropriately normal or slightly high in ACTH-dependent macronodular hyperplasia (&ge;15",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [3.3",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the ACTH-independent types of Cushing's syndrome, there are several features that are suggestive of AIMAH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with overt Cushing's syndrome due to AIMAH present in the fifth and sixth decades [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4\">",
"       1-4",
"      </a>",
"      ], a later age of onset compared with unilateral cortisol-producing adenomas, or PPNAD.",
"     </li>",
"     <li>",
"      While the typical laboratory findings of ACTH-independent Cushing's syndrome include high serum and urinary cortisol and suppressed plasma ACTH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4\">",
"       1-4",
"      </a>",
"      ], an exception to this general pattern occurs in patients with GIP-dependent Cushing's syndrome, in whom cortisol hypersecretion occurs in response to meals [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum aldosterone, 18-hydroxycorticosterone, corticosterone, and estrone may cause hypertension or feminization in the rare AIMAH patients in whom they are increased [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subclinical Cushing's syndrome in AIMAH with normal urinary free cortisol, detectable ACTH levels still responsive to CRH, but with subnormal suppression of plasma cortisol following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      has become increasingly recognized [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,15,16\">",
"       8,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Steroid hormone synthesis is inefficient in AIMAH, as a consequence of decreased steroidogenic enzymatic expression and activity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/23,32,68,79\">",
"       23,32,68,79",
"      </a>",
"      ]. Furthermore, elevated 17-hydroxyprogesterone levels occur following stimulation with ACTH providing in vivo evidence of altered adrenocortical enzymatic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. This inefficient steroidogenesis may explain the discrepancy between the sometimes subtle changes in cortisol hypersecretion such as seen in subclinical Cushing's syndrome and the massive adrenal enlargement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these steroidogenic enzyme defects, the increase in cortisol following administration of exogenous ACTH is larger than in normal adrenals and reflects the large adrenal cell mass [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This can be useful in distinguishing AIMAH from other causes of bilaterally enlarged adrenals such as metastatic or infiltrative diseases, where steroidogenic response to ACTH administration is decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of adrenal CT and MR imaging are variable, ranging from apparently unilateral nodules to massive bilateral enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/1-4,20,80\">",
"     1-4,20,80",
"    </a>",
"    ]. In one series of 12 patients, 11 had enlarged multinodular glands, with nodules 0.1 to 5.5 cm in diameter. In nine patients who underwent pituitary CT or MRI, all were normal. Adrenal scintigraphy with 131-I-labeled cholesterol showed bilateral uptake in four of five patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aberrant receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols have been developed to systematically evaluate patients with adrenal CS for the presence of aberrant adrenal hormone receptors that are frequently present in AIMAH with overt or sub-clinical Cushing's syndrome (",
"    <a class=\"graphic graphic_table graphicRef65003 \" href=\"UTD.htm?5/58/6061\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/9,10,15,16,25,36\">",
"     9,10,15,16,25,36",
"    </a>",
"    ]. The strategy is to examine whether cortisol or other steroids change in response to physiological (upright posture, mixed meals) and pharmacological (gonadotropin-releasing hormone, thyrotropin-releasing hormone, vasopressin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) tests that modulate the levels of ligands for the potential aberrant receptors.",
"   </p>",
"   <p>",
"    We recommend that all patients with AIMAH and clinical or subclinical CS undergo screening for aberrant receptors, as this may change the therapeutic strategy (",
"    <a class=\"graphic graphic_table graphicRef65003 \" href=\"UTD.htm?5/58/6061\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Screening family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members (over age 25 to 30 years) of patients with AIMAH with aberrant receptors should undergo screening for subclinical or clinical AIMAH. We suggest performing the 1 mg overnight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests; those who do not suppress their plasma cortisol on the following morning below 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    should have an adrenal CT scan. Family members who are found to have hypercortisolism should also undergo evaluation for aberrant hormone receptors. Patients with AIMAH associated with genetic causes such as MEN 1 or polyposis coli have their familial screening for other purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical bilateral adrenalectomy is uniformly effective in patients with AIMAH since this disorder is a primary adrenal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/4,6,81\">",
"     4,6,81",
"    </a>",
"    ]. Surgical adrenalectomy is indicated in all patients with AIMAH and overt Cushing's syndrome who have no evidence of aberrant hormone receptors, or who have aberrant receptors that are not be amenable to medical therapy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pharmacological therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Post-adrenalectomy, these patients are not at risk for Nelson's syndrome (corticotroph tumor progression) because the pituitary is intrinsically normal. Therefore, pituitary radiation to prevent Nelson's syndrome is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical adrenalectomy, including surgical approach and postoperative hormone replacement, is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with moderately increased cortisol production (less than twofold increase in urinary free cortisol levels), unilateral adrenalectomy often restores urinary free cortisol levels to normal [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]. However, as the cell mass subsequently increases in the contralateral adrenal, a second adrenalectomy may become necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/82-84\">",
"       82-84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with subclinical AIMAH and normal levels of urinary cortisol, the decision for therapy should be based on manifestations of cortisol excess such as hypertension, diabetes, osteoporosis, or neuropsychological manifestations. Many of these are identified as incidentalomas initially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who are being monitored without adrenal surgery, annual CT scan and biochemical assessment are sufficient, as AIMAH is a benign process that has not been shown to become malignant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacological therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacological therapy is used in two settings in AIMAH. Adrenal enzyme inhibitors are sometimes given to patients with overt Cushing's syndrome to control cortisol secretion before surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/81\">",
"     81",
"    </a>",
"    ]. In patients in whom aberrant hormone receptors have been identified, several potential therapies have been investigated as alternatives to adrenalectomy, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacological blockade of postprandial release of GIP with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"       pasireotide",
"      </a>",
"      led to clinical and biochemical improvement of Cushing's syndrome, but did not persist in the long-term, probably because of eventual desensitization of somatostatin receptors in GIP-secreting duodenal K cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/7,17,21\">",
"       7,17,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In catecholamine-dependent Cushing's syndrome and AIMAH, beta-adrenergic receptor antagonists (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ) were efficient in the long-term control of hypercortisolism [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/42,44\">",
"       42,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In",
"      <span class=\"nowrap\">",
"       LH/hCG-dependent",
"      </span>",
"      AIMAH and Cushing's syndrome, suppression of endogenous LH levels with long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate controlled steroid secretion and avoided bilateral adrenalectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When specific receptor antagonists for vasopressin, serotonin, GIP, or other aberrant receptors become available, a broader range of pharmacological therapies could become useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is possible that despite complete blockade of the aberrant receptors, tumor regression does not occur, as other genetic events inducing proliferative gain-of-function mutations (other than aberrant receptors) have accumulated over time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/45/730/abstract/16,23,85\">",
"     16,23,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACTH-independent macronodular adrenal hyperplasia (AIMAH) has been described by various terms, including massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and \"giant\" or \"huge\" macronodular adrenal disease. AIMAH results in hypercortisolism through a number of mechanisms that are described above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most prevalent abnormality in patients with AIMAH results from the aberrant adrenal expression of ectopic or increased activity of eutopic peptide hormone receptors. Cortisol secretion becomes driven by a hormone that escapes cortisol-mediated feedback. Aberrant receptors that have been identified include gastric inhibitory polypeptide (GIP), vasopressin, beta-adrenergic,",
"      <span class=\"nowrap\">",
"       LH/hCG,",
"      </span>",
"      serotonin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      , and angiotensin receptors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Aberrant hormone receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation and biochemical findings of Cushing's syndrome in AIMAH are similar to those seen in other types of ACTH-independent Cushing's syndrome. However, patients with AIMAH typically have a later age of onset (fifth and sixth decades), and patients with GIP-dependent Cushing's syndrome have a unique pattern of cortisol hypersecretion (\"food-dependent\"). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'GIP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with AIMAH and clinical or subclinical CS undergo screening for aberrant receptors, as this may change the therapeutic strategy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Aberrant hormone receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, we recommend screening of first degree relatives using 1 mg overnight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test for the presence of familial AIMAH. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Screening family members'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treatment with beta-blockers for patients with AIMAH and aberrant beta-adrenergic receptors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pharmacological therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with GnRH agonists (and sex steroid replacement) for patients with AIMAH and",
"      <span class=\"nowrap\">",
"       LH/hCG",
"      </span>",
"      receptors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pharmacological therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with AIMAH in whom aberrant hormone receptors are not present or for which no specific pharmacological blockade is available or effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest bilateral adrenalectomy for severe Cushing's syndrome (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest unilateral adrenalectomy in patients with moderately increased cortisol production (less than twofold increase in urinary free cortisol levels) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with subclinical AIMAH and normal levels of urinary cortisol, the decision for therapy should be based on manifestations of cortisol excess (hypertension, diabetes, osteoporosis, or neuropsychological manifestations).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/1\">",
"      KIRSCHNER MA, POWELL RD Jr, LIPSETT MB. CUSHING'S SYNDROME: NODULAR CORTICAL HYPERPLASIA OF ADRENAL GLANDS WITH CLINICAL AND PATHOLOGICAL FEATURES SUGGESTING ADRENOCORTICAL TUMOR. J Clin Endocrinol Metab 1964; 24:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/2\">",
"      Cheitlin RA, Westphal M, Cabrera CM, et al. Cushing's syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: cell culture of adenoma cells on extracellular matrix. Horm Res 1988; 29:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/3\">",
"      Malchoff CD, Rosa J, DeBold CR, et al. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 1989; 68:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/4\">",
"      Swain JM, Grant CS, Schlinkert RT, et al. Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation. Arch Surg 1998; 133:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/5\">",
"      Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/6\">",
"      Lacroix A, Bolt&eacute; E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 1992; 327:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/7\">",
"      Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/8\">",
"      Bourdeau I, D'Amour P, Hamet P, et al. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/9\">",
"      Lib&eacute; R, Coste J, Guignat L, et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. Eur J Endocrinol 2010; 163:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/10\">",
"      Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/11\">",
"      Wada S, Kitahama S, Togashi A, et al. Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. Intern Med 2002; 41:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/12\">",
"      Ghayee HK, Rege J, Watumull LM, et al. Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. J Clin Endocrinol Metab 2011; 96:E243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/13\">",
"      Aron DC, Findling JW, Fitzgerald PA, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/14\">",
"      Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/15\">",
"      Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/16\">",
"      Lacroix A, Baldacchino V, Bourdeau I, et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/17\">",
"      de Herder WW, Hofland LJ, Usdin TB, et al. Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996; 81:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/18\">",
"      Groussin L, Perlemoine K, Contesse V, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab 2002; 87:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/19\">",
"      N'Diaye N, Tremblay J, Hamet P, et al. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/20\">",
"      N'Diaye N, Hamet P, Tremblay J, et al. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. J Clin Endocrinol Metab 1999; 84:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/21\">",
"      Preumont V, Mermejo LM, Damoiseaux P, et al. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome. Horm Metab Res 2011; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/22\">",
"      Lampron A, Bourdeau I, Oble S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/23\">",
"      Lampron A, Bourdeau I, Hamet P, et al. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/24\">",
"      Tsagarakis S, Tsigos C, Vassiliou V, et al. Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. J Clin Endocrinol Metab 2001; 86:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/25\">",
"      Bertherat J, Contesse V, Louiset E, et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab 2005; 90:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/26\">",
"      Albiger NM, Occhi G, Mariniello B, et al. Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. Eur J Endocrinol 2007; 157:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/27\">",
"      Pralong FP, Gomez F, Guillou L, et al. Food-dependent Cushing's syndrome: possible involvement of leptin in cortisol hypersecretion. J Clin Endocrinol Metab 1999; 84:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/28\">",
"      Antonini SR, N'Diaye N, Baldacchino V, et al. Analysis of the putative regulatory region of the gastric inhibitory polypeptide receptor gene in food-dependent Cushing's syndrome. J Steroid Biochem Mol Biol 2004; 91:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/29\">",
"      Swords FM, Aylwin S, Perry L, et al. The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing's disease? J Clin Endocrinol Metab 2005; 90:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/30\">",
"      Chabre O, Liakos P, Vivier J, et al. Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: insights into hormonal control of adrenocortical tumorigenesis. J Clin Endocrinol Metab 1998; 83:3134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/31\">",
"      Baldacchino V, Oble S, D&eacute;carie PO, et al. The Sp transcription factors are involved in the cellular expression of the human glucose-dependent insulinotropic polypeptide receptor gene and overexpressed in adrenals of patients with Cushing's syndrome. J Mol Endocrinol 2005; 35:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/32\">",
"      Bourdeau I, Antonini SR, Lacroix A, et al. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene 2004; 23:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/33\">",
"      Mazzuco TL, Chabre O, Sturm N, et al. Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology 2006; 147:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/34\">",
"      Horiba N, Suda T, Aiba M, et al. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/35\">",
"      Lacroix A, Tremblay J, Touyz RM, et al. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997; 82:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/36\">",
"      Mircescu H, Jilwan J, N'Diaye N, et al. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? J Clin Endocrinol Metab 2000; 85:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/37\">",
"      Mune T, Murase H, Yamakita N, et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87:5706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/38\">",
"      Miyamura N, Taguchi T, Murata Y, et al. Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 2002; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/39\">",
"      Lee S, Hwang R, Lee J, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) 2005; 63:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/40\">",
"      Vezzosi D, Cartier D, R&eacute;gnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol 2007; 156:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/41\">",
"      Louiset E, Contesse V, Groussin L, et al. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing's syndrome: molecular, immunohistochemical and pharmacological correlates. J Endocrinol 2008; 196:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/42\">",
"      Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med 1997; 337:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/43\">",
"      Miyamura N, Tsutsumi A, Senokuchi H, et al. A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003; 50:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/44\">",
"      Mazzuco TL, Thomas M, Martinie M, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/45\">",
"      Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. N Engl J Med 1999; 341:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/46\">",
"      Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/47\">",
"      Feelders RA, Lamberts SW, Hofland LJ, et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 2003; 88:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/48\">",
"      Cartier D, Lihrmann I, Parmentier F, et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/49\">",
"      Mannelli M, Ferruzzi P, Luciani P, et al. Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88:4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/50\">",
"      Louiset E, Contesse V, Groussin L, et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:4578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/51\">",
"      Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/52\">",
"      Burgess JR, Harle RA, Tucker P, et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 1996; 131:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/53\">",
"      Swords FM, Baig A, Malchoff DM, et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002; 16:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/54\">",
"      Louiset E, Isvi K, Gasc JM, et al. Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocr Relat Cancer 2008; 15:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/55\">",
"      Nakamura Y, Son Y, Kohno Y, et al. Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001; 15:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/56\">",
"      Assie G, Louiset E, Sturm N, et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab 2010; 95:E253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/57\">",
"      Lefebvre H, Duparc C, Chartrel N, et al. Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/58\">",
"      Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/59\">",
"      Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/60\">",
"      Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994; 79:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/61\">",
"      Fragoso MC, Domenice S, Latronico AC, et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003; 88:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/62\">",
"      Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992; 75:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/63\">",
"      Yoshida M, Hiroi M, Imai T, et al. A case of ACTH-independent macronodular adrenal hyperplasia associated with multiple endocrine neoplasia type 1. Endocr J 2011; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/64\">",
"      Lee KT, Arnott RD, McLean CA, et al. Corticotropin-independent macronodular adrenal hyperplasia associated with insulinoma. Endocr Pract 2011; 17:e43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/65\">",
"      Sato M, Soma M, Nakayama T, et al. A case of adrenocorticotropin-independent bilateral adrenal macronodular hyperplasia (AIMAH) with primary hyperparathyroidism (PHPT). Endocr J 2006; 53:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/66\">",
"      Swords FM, Noon LA, King PJ, Clark AJ. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Mol Cell Endocrinol 2004; 213:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/67\">",
"      Suri D, Alonso M, Weiss RE. A case of ACTH-independent bilateral macronodular adrenal hyperplasia and severe congestive heart failure. J Endocrinol Invest 2006; 29:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/68\">",
"      Antonini SR, Baldacchino V, Tremblay J, et al. Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2006; 64:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/69\">",
"      Kartheuser A, Walon C, West S, et al. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation. J Med Genet 1999; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/70\">",
"      Matyakhina L, Freedman RJ, Bourdeau I, et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 2005; 90:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/71\">",
"      Lib&eacute; R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14:4016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/72\">",
"      Bimpaki EI, Iliopoulos D, Moraitis A, Stratakis CA. MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis. Clin Endocrinol (Oxf) 2010; 72:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/73\">",
"      Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993; 76:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/74\">",
"      Minami S, Sugihara H, Sato J, et al. ACTH independent Cushing's syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996; 44:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/75\">",
"      Nies C, Bartsch DK, Ehlenz K, et al. Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002; 110:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/76\">",
"      Im&ouml;hl M, K&ouml;ditz R, Stachon A, et al. [Catecholamine-dependent hereditary Cushing's syndrome - follow-up after unilateral adrenalectomy]. Med Klin (Munich) 2002; 97:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/77\">",
"      Someya, T, et al. Folia Endocrinol 1996 72, 762, Watson TD et al Radiology 2007; 244: 923.",
"     </a>",
"    </li>",
"    <li>",
"     Oheda, T, et al. Folia Endocrinol 1995, 71:416.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/79\">",
"      Wada N, Kubo M, Kijima H, et al. Adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia: immunohistochemical studies of steroidogenic enzymes and post-operative course in two men. Eur J Endocrinol 1996; 134:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/80\">",
"      Doppman JL, Chrousos GP, Papanicolaou DA, et al. Adrenocorticotropin-independent macronodular adrenal hyperplasia: an uncommon cause of primary adrenal hypercortisolism. Radiology 2000; 216:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/81\">",
"      Malchoff, CD, MacGillvray, D, Malchoff, DM. Adrenocortical hormone-independent adrenal hyperplasia. Endocrinologist 1996; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/82\">",
"      Boronat M, Lucas T, Barcel&oacute; B, et al. Cushing's syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy. Postgrad Med J 1996; 72:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/83\">",
"      Lamas C, Alfaro JJ, Lucas T, et al. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases. Eur J Endocrinol 2002; 146:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/84\">",
"      Iacobone M, Albiger N, Scaroni C, et al. The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 2008; 32:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/45/730/abstract/85\">",
"      Almeida MQ, Harran M, Bimpaki EI, et al. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J Clin Endocrinol Metab 2011; 96:E728.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 148 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-201.211.0.116-269EF57EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_730=[""].join("\n");
var outline_f0_45_730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Biochemical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aberrant hormone receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H596836211\">",
"      - Receptor types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vasopressin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta adrenergic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LH/hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serotonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angiotensin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428975\">",
"      - Systematic screening for aberrant receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H596836184\">",
"      Paracrine mechanisms in AIMAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Familial forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aberrant receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Screening family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacological therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/58/6061\" title=\"table 1\">",
"      Aberrant receptor screen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_45_731="Plain film signs appendicitis";
var content_f0_45_731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Plain radiographic signs of acute appendicitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Right lower quadrant fecalith",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localized ileus with air/fluid levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paucity of gas in the right lower quadrant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scoliosis concave to the right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of the psoas shadow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue mass",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_731=[""].join("\n");
var outline_f0_45_731=null;
var title_f0_45_732="Comparative cost effectiveness";
var content_f0_45_732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated cost effectiveness of various medical interventions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cost per year of life gained, in US dollars",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking cessation",
"       </td>",
"       <td>",
"        2587 to 6828",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia vaccine in elderly patients",
"       </td>",
"       <td>",
"        1500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CABG in patients with left main coronary disease and severe angina",
"       </td>",
"       <td>",
"        4329",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylketonuria screening",
"       </td>",
"       <td>",
"        7000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kidney transplantation",
"       </td>",
"       <td>",
"        9756",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical cancer screening",
"       </td>",
"       <td>",
"        10,000 to &gt;1,000,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of moderate hypertension (DBP &gt;110 mmHg)",
"       </td>",
"       <td>",
"        11,300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart transplantation",
"       </td>",
"       <td>",
"        16,239",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of mild hypertension (DBP 90 to 110 mmHg)",
"       </td>",
"       <td>",
"        24,408",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer screening",
"       </td>",
"       <td>",
"        26,800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of cholesterol &gt;265 mg/dL (6.9 mmol/L) with cholestyramine",
"       </td>",
"       <td>",
"        36,000 to &gt;1,000,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dialysis",
"       </td>",
"       <td>",
"        37,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptokinase for acute MI in patients &ge;65 years old",
"       </td>",
"       <td>",
"        55,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Croghan IT, Offord KP, Evans RW, et al, Mayo Clin Proc 1997; 72:917.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_732=[""].join("\n");
var outline_f0_45_732=null;
var title_f0_45_733="Antimicrobial prophylaxis for genitourinary surgery";
var content_f0_45_733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for genitourinary surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nature of operation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Cystoscopy alone",
"       </td>",
"       <td rowspan=\"2\">",
"        Enteric gram-negative bacilli, enterococci",
"       </td>",
"       <td>",
"        High-risk",
"        <sup>",
"         &bull;",
"        </sup>",
"        only: ciprofloxacin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg orally or 400 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        One 160/800 mg (double strength, DS) tablet orally",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cystoscopy with manipulation or upper tract instrumentation",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Enteric gram-negative bacilli, enterococci",
"       </td>",
"       <td>",
"        Ciprofloxacin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg orally or 400 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        One 160/800 mg (double strength, DS) tablet orally",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Open or laparoscopic surgery",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Enteric gram-negative bacilli, enterococci",
"       </td>",
"       <td>",
"        Cefazolin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Urine culture positive or unavailable, preoperative catheter, transrectal prostatic biopsy, or placement of prosthetic material.",
"     <br/>",
"     &Delta; Due to increasing resistance of E. coli to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Shock wave lithotripsy, ureteroscopy.",
"     <br/>",
"     &sect; Including percutaneous renal surgery, procedures with entry into the urinary tract, and those involving implantation of a prosthesis. If manipulation of bowel is involved, prophylaxis is given according to colorectal guidelines.",
"     <br/>",
"     &yen; For patients allergic to penicillins and cephalosporins, clindamycin or vancomycin with either gentamicin, ciprofloxacin, levofloxacin, or aztreonam is a reasonable alternative. Fluoroquinolones should not be used for prophylaxis in cesarean section.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_733=[""].join("\n");
var outline_f0_45_733=null;
var title_f0_45_734="Outcome surgery vs surveillance";
var content_f0_45_734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patients undergoing elective repair of an abdominal aortic aneurysm do better at eight years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the UK Small Aneurysm trial of 1090 patients with a medium-sized abdominal aortic aneurysm, there is no difference in survival with early elective surgery compared with initial surveillance. However, by eight years patients undergoing early surgery have a significantly better outcome than those in the surveillance group (P=0.05 ). I bars represent the 95 percent confidence intervals for the point estimates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The United Kingdom Small Aneurysm Trial Participants. N Engl J Med 2002; 346:1445.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_734=[""].join("\n");
var outline_f0_45_734=null;
var title_f0_45_735="Renal stones in primary oxaluria";
var content_f0_45_735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Renal stones in primary oxaluria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_45_735=[""].join("\n");
var outline_f0_45_735=null;
